Accurate selection of patients with low-risk prostate cancer for active surveillance relies upon conventional clinical staging and grading criteria. New approaches in imaging as well as novel serum-, urine- and tissue-based biomarkers have been developed to reduce initial misclassification and predict risk of disease progression.
- James L. Liu
- Hiten D. Patel
- Alan W. Partin
